Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec

Background: The introduction of novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) was an important milestone given their survival benefits, tolerability, and ease of administration relative to taxane chem...

Full description

Bibliographic Details
Main Authors: Jason Hu, Armen G. Aprikian, Ramy R. Saleh, Alice Dragomir
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Current Oncology
Subjects:
prostate cancer
abiraterone
enzalutamide
drug utilization
Online Access:https://www.mdpi.com/1718-7729/29/11/680

Similar Items

Similar Items